在杜氏肌肉发育不良的小鼠模型中,可登优化的人类Smad7基因疗法增强了骨肌肉质量和功能
Buel D Rodgers1, Christopher W Ward2
1Aavogen, Inc., Rockville, MD, USA. danrodgers@aavogen.com.
Gene therapy
|November 25, 2025
概括
优化人类Smad7基因疗法 (AVGN7.2) 在杜氏肌肉发育不良模型中改善了肌肉功能. 这种基因疗法增强了肌肉质量和力量,而不会导致进一步的退化.
科学领域:
- 基因治疗 基因治疗
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 将基因疗法从动物模型转化为人类应用,需要使用人类基因.
- 优化人类Smad7cDNA可以改善二次结构并减少与免疫相关的序列.
- 基因相关的病毒载体是基因治疗的常见传递系统.
研究的目的:
- 在临床前模型中评估优化人类Smad7 (AVGN7.2) 基因疗法的疗效.
- 评估AVGN7.2对骨肌肉缩和功能的影响.
- 为了确定AVGN7.2是否会在杜氏肌肉发育不良模型中加剧肌肉退化.
主要方法:
- 人类Smad7cDNA被优化以改善二次结构并去除负 cis 元素.
- 用热力学建模来评估二次结构改进.
- 血清型6腺相关病毒载体 (AAV6) 用于在体内输送AVGN7.2.
- 用杜氏肌肉发育不良的小鼠模型来评估功能结果.
主要成果:
- 优化的人类Smad7 (AVGN7.2) 与野生类型相比,表现出更好的二次结构.
- AAV6产生的AVGN7.2在刺激肌肉缩和增强等比扭矩方面与小鼠Smad7同样有效或更有效.
- 在杜氏肌肉衰竭模型中,AVGN7.2增加了肌肉质量和同度扭矩,同时使收缩动力学正常化.
- 治疗AVGN7.2并没有对血清肌酸激酶,纤维化或肌纤维中核核产生负面影响.
结论:
- 优化的人类Smad7 (AVGN7.2) 基因疗法可以增强衰变肌肉功能.
- AVGN7.2 改善肌肉质量和功能,而不会加剧肌肉退化.
- 使用AVGN7.2的组合方法可能为杜琴氏肌肉发育不良提供进一步的治疗益处.
相关概念视频
01:21Satellite Stem Cells and Muscular Dystrophy
2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
00:59Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K